Anti-PD-1 and anti-LAG-3 synergized in the ID8-OT-I murine model to prolong survival, reduce tumor burden, and reduce Tregs, while increasing CD4+ and CD8+ TILs [59]. Here, CD8A is linked to neoplasm.